octenidine
Commercial- Indications
- Wound infection, Skin antisepsis
Company intelligence / Profile preview
Schülke & Mayr has over a century-long track record as an innovator in infection prevention. Its portfolio includes market-leading disinfectants such as mikrozid®, antiseptics like octenisept®, and preservation solutions for medical devices and cosmetics. The company’s products are recognized for efficacy against bacteria, viruses—including SARS-CoV‑2—and fungi. It continues to expand its global reach through acquisitions such as Vesismin Health in Spain. No clinical trial results apply since the company does not develop therapeutics requiring phased trials.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Schülke & Mayr.